PECS II Block in Thoracic Outlet Decompression

Thoracic Outlet Syndrome Clinical Trial

— BLOCKTOS  

Official title:

The Use of Pectoral Nerve Block Type II in Patients Undergoing Trans-axillary Thoracic Outlet Decompression

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04471545
• Other study ID #: NL72737.100.20
• Status: Completed
• Phase: N/A
• Start date: August 27, 2020
• Est. completion date: October 3, 2021

Study information

• Verified date: March 2022
• Source: Catharina Ziekenhuis Eindhoven
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Rationale: Postoperative pain management after transaxillary thoracic outlet decompression surgery (TATOD) is difficult. In a retrospective case-control trial, we found evidence that a PECS II block is able to reduce pain and morphine consumption. This may ultimately lead to less morphine induced side-effects and improved patient satisfaction. However, the risk of bias in retrospective research is high. To determine the effect of PECS II in TATOD, a randomized controlled double blinded trial could offer more valuable scientific evidence. Our hypothesis is that a PECS II block will reduce pain, opioid use and opioid induced side-effects in patients undergoing transaxillary TOD (TATOD).

Objective: The aim of the study is to determine the effect of a PECS II block on postoperative pain and opioid use in patients undergoing TATOD. The secondary objective is to determine the effect of a PECS II block on opioid induced side effects such as postoperative nausea and vomitus and the quality of recovery Study design: Single centre randomized controlled double blinded trial Study population: All patients with Neurogenic Thoracic Outlet Syndrome (NTOS) selected for TATOD by the TOS multidisciplinary workgroup and based on the specifications in 2016 SVS reporting standards.

Intervention: The study group will receive a PECS II block with 40 ml ropivacaine 5 mg/ml. The control group will receive a PECS II block with 40 ml NaCL 0.9%.

Main study parameters/endpoints: Primary outcome parameters are postoperative pain using the Numeric Rated Scale (NRS) score assessed at rest and when moving and postoperative morphine-equivalent consumption. Secondary outcome parameters are postoperative Nausea and Vomitus (PONV) and Quality of Recovery questionnaire (QoR-15).

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: All patients will undergo ultrasound guided injection, after induction of anaesthesia. The administration of the injection does not invoke any extra physical discom-fort. Possible complications include hematoma and pneumothorax, however, the risk is very low (<1%)[1]. In the intervention group, we expect less pain, a reduced need for pain medica-tion and less postoperative nausea and vomitus. We do not expect an altered postoperative course in the control group. Patients will be asked to fill out a questionnaire. Extra blood sam-ples, site visits, physical examinations or other test will not be done in this study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 70
• Est. completion date: October 3, 2021
• Est. primary completion date: October 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with NTOS

• Selected for a trans-axillary thoracic outlet decompression (TATOD) by the TOS multidisciplinary workgroup.

• Fit for surgery, defined as ASA (American Society of Anesthesiologists) Classification of I, II or III.

• 18 years of age or older

• Sufficient in speaking and writing the Dutch language

• Normal liver and renal function

• Informed consent

Exclusion Criteria:

• Patients with a history of TOD (Redo-surgery)

• Patients with ATOS or VTOS

• ASA = 4

• Kidney or liver failure with contra-indication for NSAID or paracetamol

• Mental retardation

• Pregnancy

• Patients with chronic strong opioid use (>3 administrations per week or continuous transdermal therapy, longer than the last 3 months)

• Allergy to one or more medications used in the study including, ropivacaine, dexamethasone, propofol, sufentanil, succinylcholine, paracetamol, NSAID, morphine, granisetron

• Patients that have trouble expressing themselves in Dutch. Questionnaires are completed by the patients and checked by the nurses. The questionnaire is in Dutch. If there is a language barrier between the questionnaire, the patient or the health care worker, we believe the validity of the answers is questionable.

Related Conditions & MeSH terms

• Thoracic Outlet Syndrome

Intervention

Procedure:
• Pectoral nerve block type II
A pectoral nerve block type II will be given to the patient after induction. This is performed ultrasound guided

Locations

Country	Name	City	State
Netherlands	Catharina Ziekenhuis	Eindhoven	Noord-Brabant

Sponsors (1)

Lead Sponsor	Collaborator
Catharina Ziekenhuis Eindhoven

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Pain Numeric Rated Scale	Pain is measured using the Numeric Rated Scale (NRS) for pain. This is a psychometric response scale in which patients are asked to rate their pain from 0 to 10 (no pain to extreme pain). This scale is a validated and generally accepted tool to measure pain.	Change pain NRS scale is measured at admission, immediately after surgery and every postoperative day in the morning and in the evening from date of admission until the date of discharge
Primary	Morphine Equivalent Dose (MED)	Opioid use is measured in Morphine Equivalent Dose (MED). This is a generally accepted tool to quantify opioid use in patients. We will focus on the total opioid consumption.	Total morphine equivalent dose is measured from date of admission until the date of discharge
Secondary	Postoperative nausea and vomitus (PONV)	Postoperative nausea and/or vomitus (PONV) will be assessed by yes or no answer.	measured at admission, immediately after surgery and every postoperative day in the morning and in the evening from date of admission until the date of discharge
Secondary	Quality of Recovery Scale - 15 (QoR-15)	The QoR-15 is a recently developed and validated patient-reported outcome measurement (PROM) of postoperative quality of recovery.; Fifteen questions assess five domains of patient-reported health status: pain, physical comfort, physical independence, psychological support and emotional state. The 11-point numerical rating scale leads to a minimum score of 0 (very poor recovery) and a maximum score of 150 (excellent recovery).	measured at admission, immediately after surgery and every postoperative day in the morning and in the evening from date of admission until the date of discharge